Cargando…
Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications
BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE: To estimate the costs of treatment including the resources...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253143/ https://www.ncbi.nlm.nih.gov/pubmed/27587010 http://dx.doi.org/10.1007/s40258-016-0272-z |
_version_ | 1782498122943954944 |
---|---|
author | Kostić, Marina Djakovic, Ljiljan Šujić, Raša Godman, Brian Janković, Slobodan M. |
author_facet | Kostić, Marina Djakovic, Ljiljan Šujić, Raša Godman, Brian Janković, Slobodan M. |
author_sort | Kostić, Marina |
collection | PubMed |
description | BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn’s disease and ulcerative colitis. METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs. RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn’s disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation. CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40258-016-0272-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5253143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-52531432017-02-03 Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications Kostić, Marina Djakovic, Ljiljan Šujić, Raša Godman, Brian Janković, Slobodan M. Appl Health Econ Health Policy Original Research Article BACKGROUND: Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE: To estimate the costs of treatment including the resources used by patients with IBD in Serbia from a societal perspective. This includes both Crohn’s disease and ulcerative colitis. METHODS: This cost-of-illness study was conducted to identify direct, indirect and out-of-pocket costs of treating patients with IBD in Serbia. Patients with IBD (n = 112) completed a semi-structured questionnaire with data concerning their utilisation of heath-care resources and illness-related expenditures. All costs were calculated in Republic of Serbia dinars (RSD) at a 1-year level (2014) and subsequently converted to Euros. Median values and ranges were reported to avoid potential distortions associated with mean costs. RESULTS: Median total direct costs and total indirect costs per patient per year in patients with Crohn’s disease were 192,614.32RSD (€1602.97) and 28,014.00RSD (€233.13) and 142,267.15RSD (€1183.97) and 21,436.00RSD (€178.39), respectively, in patients with ulcerative colitis. In both groups, the greatest component of direct costs was hospitalisation. CONCLUSIONS: Costs of IBD in Serbia are lower than in more developed countries for two reasons. These include the fact that expensive biological therapy is currently under-utilised in Serbia and prices of health services are largely controlled by the State at a low level. The under-utilisation of biologicals may change with the advent of biosimilars at increasingly lower prices. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40258-016-0272-z) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-09-01 2017 /pmc/articles/PMC5253143/ /pubmed/27587010 http://dx.doi.org/10.1007/s40258-016-0272-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Article Kostić, Marina Djakovic, Ljiljan Šujić, Raša Godman, Brian Janković, Slobodan M. Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title | Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title_full | Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title_fullStr | Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title_full_unstemmed | Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title_short | Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications |
title_sort | inflammatory bowel diseases (crohn´s disease and ulcerative colitis): cost of treatment in serbia and the implications |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253143/ https://www.ncbi.nlm.nih.gov/pubmed/27587010 http://dx.doi.org/10.1007/s40258-016-0272-z |
work_keys_str_mv | AT kosticmarina inflammatoryboweldiseasescrohnsdiseaseandulcerativecolitiscostoftreatmentinserbiaandtheimplications AT djakovicljiljan inflammatoryboweldiseasescrohnsdiseaseandulcerativecolitiscostoftreatmentinserbiaandtheimplications AT sujicrasa inflammatoryboweldiseasescrohnsdiseaseandulcerativecolitiscostoftreatmentinserbiaandtheimplications AT godmanbrian inflammatoryboweldiseasescrohnsdiseaseandulcerativecolitiscostoftreatmentinserbiaandtheimplications AT jankovicslobodanm inflammatoryboweldiseasescrohnsdiseaseandulcerativecolitiscostoftreatmentinserbiaandtheimplications |